Schott, S., & Wallwiener, M. (2012). Cytotoxicity of the new antimetabolite-bisphosphonate (5-FdU-alendronate) in comparison to standard therapeutics on breast and ovarian cancer cell lines in the ATP tumor chemosensitivity assay. Investigational new drugs, 30(4), . https://doi.org/10.1007/s10637-011-9688-3
Chicago-Zitierstil (17. Ausg.)Schott, Sarah, und Markus Wallwiener. "Cytotoxicity of the New Antimetabolite-bisphosphonate (5-FdU-alendronate) in Comparison to Standard Therapeutics on Breast and Ovarian Cancer Cell Lines in the ATP Tumor Chemosensitivity Assay." Investigational New Drugs 30, no. 4 (2012). https://doi.org/10.1007/s10637-011-9688-3.
MLA-Zitierstil (9. Ausg.)Schott, Sarah, und Markus Wallwiener. "Cytotoxicity of the New Antimetabolite-bisphosphonate (5-FdU-alendronate) in Comparison to Standard Therapeutics on Breast and Ovarian Cancer Cell Lines in the ATP Tumor Chemosensitivity Assay." Investigational New Drugs, vol. 30, no. 4, 2012, https://doi.org/10.1007/s10637-011-9688-3.